Senior Translation Project Manager
About the job
- At least 3 years of hands-on experience in clinical or regulatory document translation and/or bilingual quality control, plus at least 2 years of translation project management experience in a complex, highly regulated, and multicultural environment, including managing translation vendors, using translation tools and technologies, and planning, allocating, and monitoring translation activities to meet timelines and quality standards.
- Strong familiarity with clinical and regulatory document types, including Protocols, Investigator's Brochures, Clinical Study Reports, and CTD Module 2 Clinical Summaries and Overviews, with expertise maintaining terminology consistency across documents and versions.
- Proven project management capabilities, including end-to-end project planning, scheduling, scope and change management, risk mitigation, and vendor oversight.
- Strong understanding of data protection, compliance, and controlled document management practices, including secure external sharing, audit trail maintenance, traceability, and document governance requirements.
- Business-level proficiency in spoken Mandarin, written Simplified Chinese, and spoken and written English.
- Advanced proficiency in Microsoft Office applications (Word, Excel, and PowerPoint), including expert-level Word formatting skills such as styles, templates, Track Changes, cross-referencing, automated numbering, and document version comparison.
- Hands-on experience with Computer-Assisted Translation tools, quality assurance tools, translation memory and terminology database import/export processes, and AI-enabled translation platforms designed to streamline workflows.
- Working knowledge of artificial intelligence and machine learning applications in translation technologies, including the ability to assess output quality and associated risks, establish appropriate expectations, and contribute to continuous process improvement.
- Ability to develop and implement post-editing strategies aligned with document risk classifications, regulatory requirements, and intended use.
- Ability to collaborate effectively across global teams and external business partners.
- Ability to work independently and effectively in diverse, cross-functional, and multicultural team environments.
- Strong cross-cultural awareness and sensitivity for effective collaboration across regions and cultures.
- Employment requires the legal right to work in the country where the role is based.
- Lead clinical document translations, ensuring high-quality and timely delivery.
- Streamline the translation process to achieve consistent quality, faster delivery, and cost-effectiveness.
- Collaborate with stakeholders to enhance processes and manage translation vendors for optimal performance.
- Build relationships with stakeholders and stay current with industry trends to drive continuous improvement.
- Lead and coordinate clinical document translations in line with Takeda standards, regulatory guidelines, and priorities, focusing primarily on documents delivered from medical writing.
- Act as the point of contact between internal and external stakeholders, including medical writers, other translation requestors, and translation service providers.
- Coordinate the planning, collection, and follow-up of translation requirements with stakeholders, maintaining effective communication and managing the process from planning through closing.
- Ensure compliance with translation deadlines, budget constraints, quality controls, and company and regulatory standards.
- Provide project management support and expertise to Takeda clinical teams, including gathering requirements, planning resources and budget, coordinating translation tasks, and ensuring quality control.
- Contribute to implementing and improving Takeda's translation tools, including implementing and managing its artificial-intelligence-enabled translation platform, and collaborate with information technology and other departments to ensure it meets clinical document translation needs.
- Analyze and assess deliverables from the artificial-intelligence translation platform, provide feedback to improve platform capabilities, and collaborate with artificial intelligence developers and information technology teams to optimize translation algorithms and platform efficiency.
- Coordinate subject matter expert review of post-artificial-intelligence translated documents within the platform, reconcile feedback, finalize translations, and confirm documents are accurate and ready for formatting and downstream activities.
- Mentor colleagues, share knowledge, and contribute to the development of translation and project management expertise within the organization.
- Experience in budget planning and financial management.
- Ability to embrace innovation and leverage emerging technologies, networks, and tools to improve translation project efficiency and outcomes.
- Strong analytical and problem-solving skills to develop solutions while maintaining quality, compliance, and professional integrity.
- Ability to manage multiple concurrent translation projects accurately and with attention to detail in fast-paced, deadline-driven environments.
- Ability to perform with resilience, confidence, and independence.
- Commitment to professional ethics, integrity, and confidentiality.
- Growth mindset, openness to feedback, and commitment to continuous learning and process enhancement.
About the company
Provides consulting, development, and commercialization services for drugs and medical devices through a global network to help clients accelerate development and bring products to market. A global team of experts in 53 countries offers end-to-end support across strategy, development, regulatory, manufacturing, and market access to reduce time to market, lower costs, and improve quality. The company differentiates itself with its large global presence, clear focus on speed and cost, and extensive experience across therapeutic areas. Its goal is to help clients accelerate the development of life-saving drugs and devices by delivering high-quality information, solutions, and performance.
Company Size
10,001+
Company Stage
IPO
Headquarters
Ireland
Founded
1990
Get referred to Icon
See people who can refer or advise you
Simplify's Take
What believers are saying
- Anthropic collaboration launched July 28, 2026, giving ICON a marquee AI partnership.
- Q2 2026 gross bookings rose 24.1% and net book-to-bill reached 1.51.
- Backlog climbed to $23.4 billion by June 30, 2026, improving near-term demand visibility.
What critics are saying
- ICON restates 2023-2025 revenue after Audit Committee found material weaknesses in controls.
- 2026 revenue guidance of $7.85 billion-$8.15 billion signals decline from $8.251 billion in 2025.
- Senior unsecured refinancing on August 13, 2026 raises fixed costs while margins already fell.
What makes Icon unique
- ICON’s Orbis platform embeds Claude across trial planning, enrollment risk, and protocol optimization.
- ICON’s 55-country footprint and 40,200-person delivery network support global clinical execution.
- ICON’s $23.4 billion backlog gives sponsors unusually deep revenue visibility.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Paid Vacation
401(k) Retirement Plan
Mental Health Support
Life Insurance
Flexible Work Hours
Growth & Insights and Company News
6 month growth
29%1 year growth
31%2 year growth
31%Icon PLC shares rose 2.5% in the month following its latest earnings report, underperforming the S&P 500. The company posted second-quarter adjusted earnings per share of $2.56, down 21.5% year-over-year and missing analyst estimates by 0.4%. Total revenues increased 1.4% to $2.06 billion, beating consensus estimates by 3.5%. On a constant-currency basis, revenues grew 0.4%. Icon reiterated its full-year 2026 guidance, expecting revenues between $7.85 billion and $8.15 billion. Adjusted earnings per share are forecast in the range of $10.00 to $11.00. Since the earnings release, analyst estimates have trended downward. The stock currently holds a Zacks Rank of Hold, suggesting expected in-line returns in coming months.
Insider selling: Icon (NASDAQ:ICLR) CEO sells $62,674.74 in stock. August 11, 2026 Key points. * Icon CEO Barry Edward Balfe sold 382 shares for approximately $62,675, reducing his direct holdings by 7.37%. The sale was made to cover tax withholding obligations tied to vested equity awards. * Icon reported quarterly EPS of $2.56, narrowly exceeding estimates, while revenue reached $2.06 billion and increased 2.3% year over year. * Analyst sentiment is mixed, with a consensus rating of "Hold" and an average price target of $170.40; institutional investors own 95.61% of the company. * MarketBeat previews the top five stocks to own by September 1st. Icon Plc (NASDAQ:ICLR - Get Free Report) CEO Barry Edward Balfe sold 382 shares of the stock in a transaction on Monday, August 10th. The shares were sold at an average price of $164.07, for a total value of $62,674.74. Following the sale, the chief executive officer directly owned 4,804 shares in the company, valued at approximately $788,192.28. The trade was a 7.37% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Icon price performance. Icon stock traded down $0.47 during midday trading on Tuesday, reaching $165.58. 656,816 shares of the company were exchanged, compared to its average volume of 1,388,886. The firm's 50-day simple moving average is $160.91 and its 200-day simple moving average is $134.45. Icon Plc has a 1 year low of $66.57 and a 1 year high of $203.91. The company has a market capitalization of $12.68 billion, a price-to-earnings ratio of 38.87, a P/E/G ratio of 6.82 and a beta of 1.21. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.95 and a current ratio of 0.95. Icon (NASDAQ:ICLR - Get Free Report) last released its earnings results on Thursday, July 30th. The medical research company reported $2.56 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.55 by $0.01. The company had revenue of $2.06 billion for the quarter, compared to analyst estimates of $2 billion. Icon had a net margin of 3.99% and a return on equity of 8.02%. The firm's quarterly revenue was up 2.3% on a year-over-year basis. During the same period in the prior year, the firm earned $3.26 EPS. On average, analysts anticipate that Icon Plc will post 9.57 EPS for the current year. Analyst ratings changes. ICLR has been the subject of several recent analyst reports. Leerink Partners set a $145.00 target price on shares of Icon in a research note on Thursday, May 28th. Truist Financial reissued a "buy" rating and set a $209.00 price target (up from $207.00) on shares of Icon in a research note on Friday, July 31st. UBS Group set a $160.00 price objective on Icon in a report on Wednesday, June 24th. JPMorgan Chase & Co. lifted their price objective on Icon from $130.00 to $155.00 and gave the company a "neutral" rating in a research report on Thursday, June 25th. Finally, William Blair upgraded Icon to a "strong-buy" rating in a research note on Thursday, July 30th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, seven have assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Hold" and an average price target of $170.40. Discover more Market cap calculator AI infrastructure stocks Mathematics Institutional investors weigh in on Icon. A number of institutional investors have recently bought and sold shares of ICLR. WINTON GROUP Ltd purchased a new position in Icon during the second quarter worth approximately $254,000. Daiwa Securities Group Inc. grew its stake in shares of Icon by 19.3% during the 2nd quarter. Daiwa Securities Group Inc. now owns 28,145 shares of the medical research company's stock valued at $4,094,000 after buying an additional 4,546 shares during the period. Frontier Capital Management Co. LLC grew its stake in shares of Icon by 97.6% during the 2nd quarter. Frontier Capital Management Co. LLC now owns 71,360 shares of the medical research company's stock valued at $10,379,000 after buying an additional 35,253 shares during the period. Peapack Gladstone Financial Corp acquired a new stake in shares of Icon during the 2nd quarter worth $212,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Icon by 58.7% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 781 shares of the medical research company's stock worth $113,000 after buying an additional 289 shares during the period. 95.61% of the stock is currently owned by hedge funds and other institutional investors. About Icon. Icon plc NASDAQ: ICLR is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas. Icon's service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Continue following MarketBeat Before you consider Icon, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Icon wasn't on the list. While Icon currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you'll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.
ICON plc has priced $2.15 billion in senior unsecured notes through its subsidiary, ICON Investments Six Designated Activity Company. The offering comprises three tranches: $500 million of 5.064% notes due 2029, $1.0 billion of 5.421% notes due 2031, and $650 million of 5.995% notes due 2036. The notes will be guaranteed by ICON on a senior unsecured basis. The offering is expected to close on 13 August 2026, subject to customary closing conditions. ICON intends to use proceeds to repay all outstanding borrowings under its bridge facility credit agreement, repay all outstanding senior secured term loans, and redeem its 5.809% Senior Secured Notes due 2027. Upon repayment, collateral securing ICON's revolving credit facility will be automatically released.
ICON Public Limited Company shares rose 33.2% over three months amid strengthening recovery signs in clinical research demand. Request-for-proposal flow increased 22% sequentially in Q2 2026, with Phase III programmes representing about 50% of opportunity volume. Gross bookings reached $3.68 billion, up 24.1% year-over-year, whilst net business wins totalled $3.12 billion. The book-to-bill ratio stood at 1.51X. Backlog grew 3% sequentially to $23.4 billion, improving revenue visibility. However, second-quarter adjusted EBITDA declined 21.7% year-over-year to $327.2 million, whilst adjusted earnings fell to $2.56 per share from $3.52. Higher pass-through revenues supported sales but pressured margins. Analysts expect 2026 revenues to decline 1% and earnings to fall 15.3% year-over-year.
ICON plc, a clinical research organisation, announced that shareholders approved all resolutions at its Annual General Meeting held on 31 July 2026. The resolutions, which were sent to shareholders on 26 June 2026, included the re-election of several board members and the election of new directors. The approved resolutions covered various corporate governance matters, including authorising the company to allot shares, disapply statutory pre-emption rights, and make overseas market purchases of shares. Shareholders also authorised the price range for reissuing treasury shares. Headquartered in Dublin, ICON employed approximately 40,200 people across 99 locations in 55 countries as of 30 June 2026. The company provides clinical development and commercialisation solutions to pharmaceutical, biotechnology, medical device, and public health organisations worldwide.